**IMRALDI- adalimumab injection, solution**
**Samsung Bioepis Co., Ltd.**

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use IMRALDI safely and effectively. See full prescribing information for IMRALDI.

**IMRALDI (adalimumab-xxxx) injection, for subcutaneous use**

Initial U.S. Approval: YYYY

IMRALDI (adalimumab-xxxx) is biosimilar* to HUMIRA (adalimumab) for the indications listed. (1)

**WARNING: SERIOUS INFECTIONS AND MALIGNANCY**

See full prescribing information for complete boxed warning.

**SERIOUS INFECTIONS (5.1, 6.1):**
- Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.
- Discontinue IMRALDI if a patient develops a serious infection or sepsis during treatment.
- Perform test for latent TB; if positive, start treatment for TB prior to starting IMRALDI.
- Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

**MALIGNANCY (5.2):**
- Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.

**INDICATIONS AND USAGE**

IMRALDI is a tumor necrosis factor (TNF) blocker indicated for treatment of:
- **Rheumatoid Arthritis (RA)** (1.1): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.
- **Juvenile Idiopathic Arthritis (JIA)** (1.2): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients from 4 to 17 years of age and ≥30 kg (66 lbs).
- **Psoriatic Arthritis (PsA)** (1.3): Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.
- **Ankylosing Spondylitis (AS)** (1.4): Reducing signs and symptoms in adult patients with active AS.
- **Adult Crohn's Disease (CD)** (1.5): Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.
- **Ulcerative Colitis (UC)** (1.6): Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers.
- **Plaque Psoriasis (Ps)** (1.7): The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.

**INDICATIONS AND USAGE**

* Administered by subcutaneous injection (2)
* **Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (2.1):** 40 mg every other week.
  - Some patients with RA not receiving methotrexate may benefit from increasing the frequency to 40 mg every week.

**Juvenile Idiopathic Arthritis (2.2):**
- ≥30 kg (66 lbs) and from 4 to 17 years of age: 40 mg every other week

**Adult Crohn's Disease and Ulcerative Colitis (2.3, 2.4):**
- Initial dose (Day 1): 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days)
- Second dose two weeks later (Day 15): 80 mg
- Two weeks later (Day 29): Begin a maintenance dose of 40 mg every other week.
- **For patients with Ulcerative Colitis only:** Only continue IMRALDI in patients who have shown evidence of clinical remission by eight weeks (Day 57) of therapy.

**Plaque Psoriasis (2.5):**
- 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.

---

### DOSAGE FORMS AND STRENGTHS

- Injection: 40 mg/0.8 mL in a single-dose pre-filled pen (IMRALDI Pre-filled Pen) (3)

---

### CONTRAINDICATIONS

None (4)

---

### WARNINGS AND PRECAUTIONS

- **Serious infections:** Do not start IMRALDI during an active infection. If an infection develops, monitor carefully, and stop IMRALDI if infection becomes serious (5.1)
- **Invasive fungal infections:** For patients who develop a systemic illness on IMRALDI, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (5.1)
- **Malignancies:** Incidence of malignancies was greater in adalimumab-treated patients than in controls (5.2)
- **Anaphylaxis or serious allergic reactions** may occur (5.3)
- **Hepatitis B virus reactivation:** Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop IMRALDI and begin anti-viral therapy (5.4)
- **Demyelinating disease:** Exacerbation or new onset, may occur (5.5)
- **Cytopenias, pancytopenia:** Advise patients to seek immediate medical attention if symptoms develop, and consider stopping IMRALDI (5.6)
- **Heart failure:** Worsening or new onset, may occur (5.8)
- **Lupus-like syndrome:** Stop IMRALDI if syndrome develops (5.9)

### ADVERSE REACTIONS

Most common adverse reactions (incidence >10%): infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.**

---

### DRUG INTERACTIONS

- **Abatacept:** Increased risk of serious infection (5.1, 5.11, 7.2)
- **Anakinra:** Increased risk of serious infection (5.1, 5.7, 7.2)
- **Live vaccines:** Avoid use with IMRALDI (5.10, 7.3)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

* Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.

**Revised: 1/2018**
FULL PRESCRIBING INFORMATION

WARNING: SERIOUS INFECTIONS AND MALIGNANCY

SERIOUS INFECTIONS

Patients treated with adalimumab products are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue IMRALDI if a patient develops a serious infection or sepsis.

Reported infections include:

- Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before IMRALDI use and during therapy. Initiate treatment for latent TB prior to IMRALDI use.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with IMRALDI prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with IMRALDI, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE
1.1 Rheumatoid Arthritis
IMRALDI is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. IMRALDI can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

1.2 Juvenile Idiopathic Arthritis
IMRALDI is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and ≥ 30 kg (66 lbs). IMRALDI can be used alone or in combination with methotrexate.

1.3 Psoriatic Arthritis
IMRALDI is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. IMRALDI can be used alone or in combination with non-biologic DMARDs.

1.4 Ankylosing Spondylitis
IMRALDI is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.

1.5 Adult Crohn's Disease
IMRALDI is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. IMRALDI is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

1.6 Ulcerative Colitis
IMRALDI is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7)].

1.7 Plaque Psoriasis
IMRALDI is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. IMRALDI should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning and Warnings and Precautions (5)].

2 DOSAGE AND ADMINISTRATION
IMRALDI is administered by subcutaneous injection.

2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
The recommended dose of IMRALDI for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDs, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with IMRALDI. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosing
frequency of IMRALDI to 40 mg every week.

2.2 Juvenile Idiopathic Arthritis

The recommended dose of IMRALDI for patients from 4 years of age and ≥ 30 kg (66 lbs) with polyarticular juvenile idiopathic arthritis (JIA) is 40 mg administered every other week via subcutaneous injection. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with IMRALDI.

Adalimumab has not been studied in patients with polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.

2.3 Adult Crohn’s Disease

The recommended IMRALDI dose regimen for adult patients with Crohn’s disease (CD) is 160 mg initially on Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a maintenance dose of 40 mg every other week. Aminosalicylates and/or corticosteroids may be continued during treatment with IMRALDI. Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] or MTX may be continued during treatment with IMRALDI if necessary. The use of adalimumab in CD beyond one year has not been evaluated in controlled clinical studies.

2.4 Ulcerative Colitis

The recommended IMRALDI dose regimen for adult patients with ulcerative colitis (UC) is 160 mg initially on Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) continue with a dose of 40 mg every other week.

Only continue IMRALDI in patients who have shown evidence of clinical remission by eight weeks (Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment with IMRALDI. Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] may be continued during treatment with IMRALDI if necessary.

2.5 Plaque Psoriasis

The recommended dose of IMRALDI for adult patients with plaque psoriasis (Ps) is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose. The use of adalimumab in moderate to severe chronic Ps beyond one year has not been evaluated in controlled clinical studies.

2.6 Monitoring to Assess Safety

Prior to initiating IMRALDI and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection [see Warnings and Precautions (5.1)].

2.7 General Considerations for Administration

IMRALDI is intended for use under the guidance and supervision of a physician. A patient may self-inject IMRALDI or a caregiver may inject IMRALDI using the IMRALDI Pre-filled Pen if a physician determines that it is appropriate, and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.

You may leave IMRALDI at room temperature for about 15 to 30 minutes before injecting. Do not remove the cap while allowing it to reach room temperature. Carefully inspect the solution in the IMRALDI Pre-filled Pen for particulate matter and discoloration prior to subcutaneous administration. If particulates and discolorations are noted, do not use the product. IMRALDI does not contain preservatives; therefore, discard unused portions of drug remaining from the pen.
Instruct patients using the IMRALDI Pre-filled Pen to inject the full amount in the pen, according to the directions provided in the Instructions for Use [see Instructions for Use].

Injections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do not give injections into areas where the skin is tender, bruised, red or hard.

3 DOSAGE FORMS AND STRENGTHS

- **Pre-filled Pen**
  Injection: 40 mg/0.8 mL of IMRALDI is provided by a single-dose pre-filled pen (IMRALDI Pre-filled Pen), containing a 1 mL pre-filled glass syringe with a fixed 29 gauge and ½ inch needle.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Serious Infections

Patients treated with adalimumab products are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death [see Boxed Warning]. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidiodomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.

The concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher risk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant use of IMRALDI and these biologic products is not recommended in the treatment of patients with RA [see Warnings and Precautions (5.7, 5.11) and Drug Interactions (7.2)].

Treatment with IMRALDI should not be initiated in patients with an active infection, including localized infections. Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. Consider the risks and benefits of treatment prior to initiating therapy in patients:

- with chronic or recurrent infection;
- who have been exposed to tuberculosis;
- with a history of an opportunistic infection;
- who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidiodomycosis, or blastomycosis; or
- with underlying conditions that may predispose them to infection.

**Tuberculosis**

Cases of reactivation of tuberculosis and new onset tuberculosis infections have been reported in patients receiving adalimumab products, including patients who have previously received treatment for latent or active tuberculosis. Reports included cases of pulmonary and extrapulmonary (i.e., disseminated) tuberculosis. Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating IMRALDI and periodically during therapy.

Treatment of latent tuberculosis infection prior to therapy with TNF blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Prior to initiating IMRALDI, assess if treatment for latent tuberculosis is needed; and consider an induration of ≥ 5 mm a positive tuberculin skin test result, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).

Consider anti-tuberculosis therapy prior to initiation of IMRALDI in patients with a past history of
latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients treated with adalimumab products. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti- tuberculosis therapy is appropriate for an individual patient.

Strongly consider tuberculosis in the differential diagnosis in patients who develop a new infection during IMRALDI treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

**Monitoring**

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with IMRALDI, including the development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Tests for latent tuberculosis infection may also be falsely negative while on therapy with IMRALDI.

Discontinue IMRALDI if a patient develops a serious infection or sepsis. For a patient who develops a new infection during treatment with IMRALDI, closely monitor them, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and initiate appropriate antimicrobial therapy.

**Invasive Fungal Infections**

If patients develop a serious systemic illness and they reside or travel in regions where mycoses are endemic, consider invasive fungal infection in the differential diagnosis. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider appropriate empiric antifungal therapy, taking into account both the risk for severe fungal infection and the risks of antifungal therapy, while a diagnostic workup is being performed. To aid in the management of such patients, consider consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections.

**5.2 Malignancies**

Consider the risks and benefits of TNF-blocker treatment including adalimumab products prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing a TNF blocker in patients who develop a malignancy.

**Malignancies in Adults**

In the controlled portions of clinical trials of some TNF-blockers, including adalimumab products, more cases of malignancies have been observed among TNF-blocker-treated adult patients compared to control-treated adult patients. During the controlled portions of 39 global adalimumab clinical trials in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn's disease (CD), ulcerative colitis (UC), plaque psoriasis (Ps), hidradenitis suppurativa (HS) and uveitis (UV), malignancies, other than non-melanoma (basal cell and squamous cell) skin cancer, were observed at a rate (95% confidence interval) of 0.7 (0.48, 1.03) per 100 patient-years among 7973 adalimumab-treated patients versus a rate of 0.7 (0.41, 1.17) per 100 patient-years among 4848 control-treated patients (median duration of treatment of 4 months for adalimumab-treated patients and 4 months for control-treated patients). In 52 global controlled and uncontrolled clinical trials of adalimumab in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV the most frequently observed malignancies, other than lymphoma and NMSC, were breast, colon, prostate, lung, and melanoma. The malignancies in adalimumab-treated patients in the controlled and uncontrolled portions of the studies were similar in type and number to what would be expected in the general U.S. population according to the SEER database (adjusted for age, gender, and race).\(^1\)
In controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener's granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.

**Non-Melanoma Skin Cancer**

During the controlled portions of 39 global adalimumab clinical trials in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, 1.09) per 100 patient-years among adalimumab-treated patients and 0.2 (0.10, 0.59) per 100 patient-years among control-treated patients. Examine all patients, and in particular patients with a medical history of prior prolonged immunosuppressant therapy or psoriasis patients with a history of PUVA treatment for the presence of NMSC prior to and during treatment with adalimumab.

**Lymphoma and Leukemia**

In the controlled portions of clinical trials of all the TNF-blockers in adults, more cases of lymphoma have been observed among TNF-blocker-treated patients compared to control-treated patients. In the controlled portions of 39 global adalimumab clinical trials in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV, 2 lymphomas occurred among 7973 adalimumab-treated patients versus 1 among 4848 control-treated patients. In 52 global controlled and uncontrolled clinical trials of adalimumab in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV with a median duration of approximately 0.7 years, including 24,605 patients and over 40,125 patient-years of adalimumab, the observed rate of lymphomas was approximately 0.11 per 100 patient-years. This is approximately 3-fold higher than expected in the general U.S. population according to the SEER database (adjusted for age, gender, and race). Rates of lymphoma in clinical trials of adalimumab cannot be compared to rates of lymphoma in clinical trials of other TNF blockers and may not predict the rates observed in a broader patient population. Patients with RA and other chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF blockers. Postmarketing cases of acute and chronic leukemia have been reported in association with TNF-blocker use in RA and other indications. Even in the absence of TNF-blocker therapy, patients with RA may be at a higher risk (approximately 2-fold) than the general population for the development of leukemia.

**Malignancies in Pediatric Patients and Young Adults**

Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blockers (initiation of therapy ≤ 18 years of age), of which adalimumab products are a member [see Boxed Warning]. Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported post-marketing and are derived from a variety of sources including registries and spontaneous postmarketing reports.

Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products [see Boxed Warning]. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with the immunosuppressants azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants. The potential risk with the combination of azathioprine or 6-mercaptopurine and IMRALDI should be carefully considered.
5.3 Hypersensitivity Reactions

Anaphylaxis and angioneurotic edema have been reported following administration of adalimumab products. If an anaphylactic or other serious allergic reaction occurs, immediately discontinue administration of IMRALDI and institute appropriate therapy. In clinical trials of adalimumab products in adults, allergic reactions (e.g., allergic rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, urticaria) have been observed.

5.4 Hepatitis B Virus Reactivation

Use of TNF blockers, including adalimumab products, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy. Exercise caution in prescribing TNF blockers for patients identified as carriers of HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV reactivation. For patients who are carriers of HBV and require treatment with TNF blockers, closely monitor such patients for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, stop IMRALDI and initiate effective anti-viral therapy with appropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV reactivation is controlled is not known. Therefore, exercise caution when considering resumption of IMRALDI therapy in this situation and monitor patients closely.

5.5 Neurologic Reactions

Use of TNF blocking agents, including adalimumab products, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and peripheral demyelinating disease, including Guillain-Barré syndrome. Exercise caution in considering the use of IMRALDI in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of IMRALDI should be considered if any of these disorders develop.

5.6 Hematological Reactions

Rare reports of pancytopenia including aplastic anemia have been reported with TNF blocking agents. Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., thrombocytopenia, leukopenia) have been infrequently reported with adalimumab. The causal relationship of these reports to adalimumab remains unclear. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on IMRALDI. Consider discontinuation of IMRALDI therapy in patients with confirmed significant hematologic abnormalities.

5.7 Use with Anakinra

Concurrent use of anakinra (an interleukin-1 antagonist) and another TNF-blocker, was associated with a greater proportion of serious infections and neutropenia and no added benefit compared with the TNF-blocker alone in patients with RA. Therefore, the combination of IMRALDI and anakinra is not recommended [see Drug Interactions (7.2)].

5.8 Heart Failure

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cases of worsening CHF have also been observed with adalimumab products. Adalimumab
has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed. Exercise caution when using IMRALDI in patients who have heart failure and monitor them carefully.

5.9 Autoimmunity

Treatment with IMRALDI may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with IMRALDI, discontinue treatment [see Adverse Reactions (6.1)].

5.10 Immunizations

In a placebo-controlled clinical trial of patients with RA, no difference was detected in anti-pneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. The clinical significance of this is unknown. Patients on IMRALDI may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving adalimumab products.

It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating IMRALDI therapy. Patients on IMRALDI may receive concurrent vaccinations, except for live vaccines.

The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].

5.11 Use with Abatacept

In controlled trials, the concurrent administration of TNF-blockers and abatacept was associated with a greater proportion of serious infections than the use of a TNF-blocker alone; the combination therapy, compared to the use of a TNF-blocker alone, has not demonstrated improved clinical benefit in the treatment of RA. Therefore, the combination of abatacept with TNF-blockers including adalimumab products is not recommended [see Drug Interactions (7.2)].

6 ADVERSE REACTIONS

The most serious adverse reactions described elsewhere in the labeling include the following:

- Serious Infections [see Warnings and Precautions (5.1)]
- Malignancies [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reaction with adalimumab was injection site reactions. In placebo-controlled trials, 20% of patients treated with adalimumab developed injection site reactions (erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of patients receiving placebo. Most injection site reactions were described as mild and generally did not necessitate drug discontinuation.

The proportion of patients who discontinued treatment due to adverse reactions during the double-blind, placebo-controlled portion of studies in patients with RA (i.e., Studies RA-I, RA-II, RA-III and RA-IV) was 7% for patients taking adalimumab and 4% for placebo-treated patients. The most common adverse
reactions leading to discontinuation of adalimumab in these RA studies were clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%).

**Infections**

In the controlled portions of the 39 global adalimumab clinical trials in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV, the rate of serious infections was 4.3 per 100 patient-years in 7973 adalimumab-treated patients versus a rate of 2.9 per 100 patient-years in 4848 control-treated patients. Serious infections observed included pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellulitis, diverticulitis, and pyelonephritis [see Warnings and Precautions (5.1)].

**Tuberculosis and Opportunistic Infections**

In 52 global controlled and uncontrolled clinical trials in RA, PsA, AS, CD, UC, Ps, HS and UV that included 24,605 adalimumab-treated patients, the rate of reported active tuberculosis was 0.20 per 100 patient-years and the rate of positive PPD conversion was 0.09 per 100 patient-years. In a subgroup of 10,113 U.S. and Canadian adalimumab-treated patients, the rate of reported active TB was 0.05 per 100 patient-years and the rate of positive PPD conversion was 0.07 per 100 patient-years. These trials included reports of miliary, lymphatic, peritoneal, and pulmonary TB. Most of the TB cases occurred within the first eight months after initiation of therapy and may reflect recrudescence of latent disease. In these global clinical trials, cases of serious opportunistic infections have been reported at an overall rate of 0.05 per 100 patient-years. Some cases of serious opportunistic infections and TB have been fatal [see Warnings and Precautions (5.1)].

**Autoantibodies**

In the rheumatoid arthritis controlled trials, 12% of patients treated with adalimumab and 7% of placebo-treated patients that had negative baseline ANA titers developed positive titers at week 24. Two patients out of 3046 treated with adalimumab developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved following discontinuation of therapy. No patients developed lupus nephritis or central nervous system symptoms. The impact of long-term treatment with adalimumab on the development of autoimmune diseases is unknown.

**Liver Enzyme Elevations**

There have been reports of severe hepatic reactions including acute liver failure in patients receiving TNF-blockers. In controlled Phase 3 trials of adalimumab (40 mg SC every other week) in patients with RA, PsA, and AS with control period duration ranging from 4 to 104 weeks, ALT elevations ≥ 3 x ULN occurred in 3.5% of adalimumab-treated patients and 1.5% of control-treated patients. Since many of these patients in these trials were also taking medications that cause liver enzyme elevations (e.g., NSAIDS, MTX), the relationship between adalimumab and the liver enzyme elevations is not clear. In a controlled Phase 3 trial of adalimumab in patients with polyarticular JIA who were 4 to 17 years, ALT elevations ≥ 3 x ULN occurred in 4.4% of adalimumab-treated patients and 1.5% of control-treated patients. In controlled Phase 3 trials of adalimumab (initial doses of 160 mg and 80 mg on Days 1 and 15, respectively, followed by 40 mg every other week) in adult patients with CD with a control period duration ranging from 4 to 52 weeks, ALT elevations ≥ 3 x ULN occurred in 0.9% of adalimumab-treated patients and 0.9% of control-treated patients. In controlled Phase 3 trials of adalimumab (initial doses of 160 mg and 80 mg on Days 1 and 15 respectively, followed by 40 mg every other week) in patients with UC with control period duration ranging from 1 to 52 weeks, ALT elevations ≥ 3 x ULN occurred in 1.5% of adalimumab-treated patients and 1.0% of control-treated patients. In controlled Phase 3 trials of adalimumab (initial dose of 80 mg then 40 mg every other week) in patients with Ps with control period duration ranging from 12 to 24 weeks, ALT elevations ≥ 3 x ULN occurred in 1.8% of adalimumab-treated patients and 1.8% of control-treated patients.
Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to adalimumab in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

Patients in Studies RA-I, RA-II, and RA-III were tested at multiple time points for antibodies to adalimumab during the 6- to 12-month period. Approximately 5% (58 of 1062) of adult RA patients receiving adalimumab developed low-titer antibodies to adalimumab at least once during treatment, which were neutralizing \textit{in vivo}. Patients treated with concomitant methotrexate (MTX) had a lower rate of antibody development than patients on adalimumab monotherapy (1% versus 12%). No apparent correlation of antibody development to adverse reactions was observed. With monotherapy, patients receiving every other week dosing may develop antibodies more frequently than those receiving weekly dosing. In patients receiving the recommended dosage of 40 mg every other week as monotherapy, the ACR 20 response was lower among antibody-positive patients than among antibody-negative patients. The long-term immunogenicity of adalimumab products is unknown.

In patients with polyarticular JIA who were 4 to 17 years of age, adalimumab antibodies were identified in 16% of adalimumab-treated patients. In patients receiving concomitant MTX, the incidence was 6% compared to 26% with adalimumab monotherapy.

In patients with AS, the rate of development of antibodies to adalimumab in adalimumab-treated patients was comparable to patients with RA.

In patients with PsA, the rate of antibody development in patients receiving adalimumab monotherapy was comparable to patients with RA; however, in patients receiving concomitant MTX the rate was 7% compared to 1% in RA.

In adult patients with CD, the rate of antibody development was 3%.

In patients with moderately to severely active UC, the rate of antibody development in patients receiving adalimumab was 5%. However, due to the limitation of the assay conditions, antibodies to adalimumab could be detected only when serum adalimumab levels were < 2 mcg/mL. Among the patients whose serum adalimumab levels were < 2 mcg/mL (approximately 25% of total patients studied), the immunogenicity rate was 20.7%.

In patients with Ps, the rate of antibody development with adalimumab monotherapy was 8%. However, due to the limitation of the assay conditions, antibodies to adalimumab could be detected only when serum adalimumab levels were < 2 mcg/mL. Among the patients whose serum adalimumab levels were < 2 mcg/mL (approximately 40% of total patients studied), the immunogenicity rate was 20.7%. In Ps patients who were on adalimumab monotherapy and subsequently withdrawn from the treatment, the rate of antibodies to adalimumab after retreatment was similar to the rate observed prior to withdrawal.

The data reflect the percentage of patients whose test results were considered positive for antibodies to adalimumab or titers, and are highly dependent on the assay. The observed incidence of antibody (including neutralizing antibody) positivity in an assay is highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to adalimumab with the incidence of antibodies to other products may be misleading.

Other Adverse Reactions

Rheumatoid Arthritis Clinical Studies

The data described below reflect exposure to adalimumab in 2468 patients, including 2073 exposed for
6 months, 1497 exposed for greater than one year and 1380 in adequate and well-controlled studies (Studies RA-I, RA-II, RA-III, and RA-IV). Adalimumab was studied primarily in placebo-controlled trials and in long-term follow up studies for up to 36 months duration. The population had a mean age of 54 years, 77% were female, 91% were Caucasian and had moderately to severely active rheumatoid arthritis. Most patients received 40 mg adalimumab every other week.

Table 1 summarizes reactions reported at a rate of at least 5% in patients treated with adalimumab 40 mg every other week compared to placebo and with an incidence higher than placebo. In Study RA-III, the types and frequencies of adverse reactions in the second year open-label extension were similar to those observed in the one-year double-blind portion.

Table 1. Adverse Reactions Reported by ≥ 5% of Patients Treated with Adalimumab During Placebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV)

<table>
<thead>
<tr>
<th>Adverse Reaction (Preferred Term)</th>
<th>Adalimumab 40 mg subcutaneous Every Other Week (N=705)</th>
<th>Placebo (N=690)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper respiratory infection</td>
<td>17%</td>
<td>13%</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>11%</td>
<td>9%</td>
</tr>
<tr>
<td>Flu syndrome</td>
<td>7%</td>
<td>6%</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>9%</td>
<td>8%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td><strong>Laboratory Tests</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory test abnormal</td>
<td>8%</td>
<td>7%</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>6%</td>
<td>4%</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>7%</td>
<td>5%</td>
</tr>
<tr>
<td>Hematuria</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Alkaline phosphatase increased</td>
<td>5%</td>
<td>3%</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>12%</td>
<td>8%</td>
</tr>
<tr>
<td>Rash</td>
<td>12%</td>
<td>6%</td>
</tr>
<tr>
<td>Accidental injury</td>
<td>10%</td>
<td>8%</td>
</tr>
<tr>
<td>Injection site reaction **</td>
<td>8%</td>
<td>1%</td>
</tr>
<tr>
<td>Back pain</td>
<td>6%</td>
<td>4%</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>8%</td>
<td>5%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>5%</td>
<td>3%</td>
</tr>
</tbody>
</table>

* Laboratory test abnormalities were reported as adverse reactions in European trials
** Does not include injection site erythema, itching, hemorrhage, pain or swelling

Less Common Adverse Reactions in Rheumatoid Arthritis Clinical Studies

Other infrequent serious adverse reactions that do not appear in the Warnings and Precautions or Adverse Reaction sections that occurred at an incidence of less than 5% in adalimumab-treated patients in RA studies were:

**Body As A Whole:** Pain in extremity, pelvic pain, surgery, thorax pain

**Cardiovascular System:** Arrhythmia, atrial fibrillation, chest pain, coronary artery disorder, heart arrest,
hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, pericarditis, syncope, tachycardia

**Digestive System:** Cholecystitis, cholelithiasis, esophagitis, gastroenteritis, gastrointestinal hemorrhage, hepatic necrosis, vomiting

**Endocrine System:** Parathyroid disorder

**Hemic And Lymphatic System:** Agranulocytosis, polycythemia

**Metabolic And Nutritional Disorders:** Dehydration, healing abnormal, ketosis, paraproteinemia, peripheral edema

**Musculo-Skeletal System:** Arthritis, bone disorder, bone fracture (not spontaneous), bone necrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon disorder

**Neoplasia:** Adenoma

**Nervous System:** Confusion, paresthesia, subdural hematoma, tremor

**Respiratory System:** Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion

**Special Senses:** Cataract

**Thrombosis:** Thrombosis leg

**Urogenital System:** Cystitis, kidney calculus, menstrual disorder

**Juvenile Idiopathic Arthritis Clinical Studies**

In general, the adverse reactions in the adalimumab-treated patients in the polyarticular juvenile idiopathic arthritis (JIA) trial (Study JIA-I) were similar in frequency and type to those seen in adult patients [see Warnings and Precautions (5), Adverse Reactions (6)]. Important findings and differences from adults are discussed in the following paragraphs.

In Study JIA-I, adalimumab was studied in 171 patients who were 4 to 17 years of age, with polyarticular JIA. Severe adverse reactions reported in the study included neutropenia, streptococcal pharyngitis, increased aminotransferases, herpes zoster, myositis, metrorrhagia, and appendicitis. Serious infections were observed in 4% of patients within approximately 2 years of initiation of treatment with adalimumab and included cases of herpes simplex, pneumonia, urinary tract infection, pharyngitis, and herpes zoster.

In Study JIA-I, 45% of patients experienced an infection while receiving adalimumab with or without concomitant MTX in the first 16 weeks of treatment. The types of infections reported in adalimumab-treated patients were generally similar to those commonly seen in polyarticular JIA patients who are not treated with TNF blockers. Upon initiation of treatment, the most common adverse reactions occurring in this patient population treated with adalimumab were injection site pain and injection site reaction (19% and 16%, respectively). A less commonly reported adverse event in patients receiving adalimumab was granuloma annulare which did not lead to discontinuation of adalimumab treatment.

In the first 48 weeks of treatment in Study JIA-I, non-serious hypersensitivity reactions were seen in approximately 6% of patients and included primarily localized allergic hypersensitivity reactions and allergic rash.

In Study JIA-I, 10% of patients treated with adalimumab who had negative baseline anti-dsDNA antibodies developed positive titers after 48 weeks of treatment. No patient developed clinical signs of autoimmunity during the clinical trial.

Approximately 15% of patients treated with adalimumab developed mild-to-moderate elevations of creatine phosphokinase (CPK) in Study JIA-I. Elevations exceeding 5 times the upper limit of normal were observed in several patients. CPK levels decreased or returned to normal in all patients. Most patients were able to continue adalimumab without interruption.
Psoriatic Arthritis and Ankylosing Spondylitis Clinical Studies

Adalimumab has been studied in 395 patients with psoriatic arthritis (PsA) in two placebo-controlled trials and in an open label study and in 393 patients with ankylosing spondylitis (AS) in two placebo-controlled studies. The safety profile for patients with PsA and AS treated with adalimumab 40 mg every other week was similar to the safety profile seen in patients with RA, adalimumab Studies RA-I through IV.

Adult Crohn's Disease Clinical Studies

Adalimumab has been studied in 1478 adult patients with Crohn's disease (CD) in four placebo-controlled and two open-label extension studies. The safety profile for adult patients with CD treated with adalimumab was similar to the safety profile seen in patients with RA.

Ulcerative Colitis Clinical Studies

Adalimumab has been studied in 1010 patients with ulcerative colitis (UC) in two placebo-controlled studies and one open-label extension study. The safety profile for patients with UC treated with adalimumab was similar to the safety profile seen in patients with RA.

Plaque Psoriasis Clinical Studies

Adalimumab has been studied in 1696 subjects with plaque psoriasis (Ps) in placebo-controlled and open-label extension studies. The safety profile for subjects with Ps treated with adalimumab was similar to the safety profile seen in subjects with RA with the following exceptions. In the placebo-controlled portions of the clinical trials in Ps subjects, adalimumab-treated subjects had a higher incidence of arthralgia when compared to controls (3% vs. 1%).

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of adalimumab products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal disorders: Diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis

General disorders and administration site conditions: Pyrexia

Hepato-biliary disorders: Liver failure, hepatitis

Immune system disorders: Sarcoidosis

Neoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell Carcinoma (neuroendocrine carcinoma of the skin)

Nervous system disorders: Demyelinating disorders (e.g., optic neuritis, Guillain-Barré syndrome), cerebrovascular accident

Respiratory disorders: Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism

Skin reactions: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia

Vascular disorders: Systemic vasculitis, deep vein thrombosis

7 DRUG INTERACTIONS

7.1 Methotrexate

Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either adalimumab or MTX [see Clinical Pharmacology (12.3)].
7.2 Biological Products

In clinical studies in patients with RA, an increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of IMRALDI with abatacept or anakinra is not recommended in patients with RA [see Warnings and Precautions (5.7 and 5.11)]. A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker. There is insufficient information regarding the concomitant use of adalimumab and other biologic products for the treatment of RA, PsA, AS, CD, UC and Ps. Concomitant administration of IMRALDI with other biologic DMARDs (e.g., anakinra and abatacept) or other TNF blockers is not recommended based upon the possible increased risk for infections and other potential pharmacological interactions.

7.3 Live Vaccines

Avoid the use of live vaccines with IMRALDI [see Warnings and Precautions (5.10)].

7.4 Cytochrome P450 Substrates

The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα, IL-6) during chronic inflammation. It is possible for a molecule that antagonizes cytokine activity, such as adalimumab, to influence the formation of CYP450 enzymes. Upon initiation or discontinuation of IMRALDI in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Limited clinical data are available from the Humira Pregnancy Registry. Excluding lost-to follow-up, data from the registry reports a rate of 5.6% for major birth defects with first trimester use of adalimumab in pregnant women with rheumatoid arthritis (RA), and a rate of 7.8% and 5.5% for major birth defects in the disease-matched and non-disease comparison groups [see Data]. Adalimumab is actively transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in-utero exposed infant [see Clinical Considerations]. In an embryo-fetal perinatal development study conducted in cynomolgus monkeys, no fetal harm or malformations were observed with intravenous administration of adalimumab during organogenesis and later in gestation, at doses that produced exposures up to approximately 373 times the maximum recommended human dose (MRHD) of 40 mg subcutaneous without methotrexate [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and miscarriage is 15-20%, respectively.

Clinical Considerations

Fetal/Neonatal adverse reactions

Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester [see Data]. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to adalimumab products in utero [see Use in Specific Populations (8.4)].

Data

Human Data
In a prospective cohort pregnancy exposure registry conducted in the U.S. and Canada between 2004 and 2013, 74 women with RA treated with adalimumab at least during the first trimester, 80 women with RA not treated with adalimumab and 218 women without RA (non-diseased) were enrolled. Excluding lost-to-follow-up, the rate of major defects in the adalimumab-exposed pregnancies (N=72), disease-matched (N=77), and non-diseased comparison groups (N=201) was 5.6%, 7.8% and 5.5%, respectively. However, this study cannot definitely establish the absence of any risk because of methodological limitations, including small sample size and nonrandomized study design. Data from the Crohn's disease portion of the study is in the follow-up phase and the analysis is ongoing.

In an independent clinical study conducted in ten pregnant women with inflammatory bowel disease treated with adalimumab, adalimumab concentrations were measured in maternal serum as well as in cord blood (n=10) and infant serum (n=8) on the day of birth. The last dose of adalimumab was given between 1 and 56 days prior to delivery. Adalimumab concentrations were 0.16-19.7 μg/mL in cord blood, 4.28-17.7 μg/mL in infant serum, and 0-16.1 μg/mL in maternal serum. In all but one case, the cord blood level of adalimumab was higher than the maternal serum level, suggesting adalimumab actively crosses the placenta. In addition, one infant had serum levels at each of the following: 6 weeks (1.94 μg/mL), 7 weeks (1.31 μg/mL), 8 weeks (0.93 μg/mL), and 11 weeks (0.53 μg/mL), suggesting adalimumab can be detected in the serum of infants exposed in utero for at least 3 months from birth.

**Animal Data**

In an embryo-fetal perinatal development study, pregnant cynomolgus monkeys received adalimumab from gestation days 20 to 97 at doses that produced exposures up to 373 times that achieved with the MRHD without methotrexate (on an AUC basis with maternal IV doses up to 100 mg/kg/week). Adalimumab did not elicit harm to the fetuses or malformations.

**8.2 Lactation**

**Risk Summary**

Limited data from case reports in the published literature describe the presence of adalimumab in human milk at infant doses of 0.1% to 1% of the maternal serum level. There are no reports of adverse effects of adalimumab on the breastfed infant and no effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for adalimumab and any potential adverse effects on the breastfed child from adalimumab or from the underlying maternal condition.

**8.4 Pediatric Use**

Safety and efficacy of adalimumab products in pediatric patients for uses other than polyarticular juvenile idiopathic arthritis (JIA) and pediatric Crohn's disease have not been established. Due to its inhibition of TNFα, adalimumab products administered during pregnancy could affect immune response in the in utero-exposed newborn and infant. Data from eight infants exposed to adalimumab in utero suggest adalimumab crosses the placenta [see Use in Specific Populations (8.1)]. The clinical significance of elevated adalimumab levels in infants is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

Post-marketing cases of lymphoma, including hepatosplenic T-cell lymphoma and other malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blockers including adalimumab products [see Boxed Warning and Warnings and Precautions (5.2)].

**Juvenile Idiopathic Arthritis**

In Study JIA-I, adalimumab was shown to reduce signs and symptoms of active polyarticular JIA in patients 4 to 17 years of age [see Clinical Studies (14.2)]. Adalimumab products have not been studied in patients with polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.
The safety of adalimumab products in patients in the polyarticular JIA trials was generally similar to that observed in adults with certain exceptions [see Adverse Reactions (6.1)].

8.5 Geriatric Use
A total of 519 RA patients 65 years of age and older, including 107 patients 75 years of age and older, received adalimumab in clinical studies RA-I through IV. No overall difference in effectiveness was observed between these patients and younger patients. The frequency of serious infection and malignancy among adalimumab treated patients over 65 years of age was higher than for those under 65 years of age. Because there is a higher incidence of infections and malignancies in the elderly population, use caution when treating the elderly.

10 OVERDOSAGE
Doses up to 10 mg/kg have been administered to patients in clinical trials without evidence of dose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.

11 DESCRIPTION
Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.

IMRALDI is supplied as a sterile, preservative-free solution of adalimumab for subcutaneous administration. The drug product is supplied as a single-dose, pre-filled pen (IMRALDI Pre-filled Pen). Enclosed within the pre-filled pen is a single-dose, 1 mL pre-filled glass syringe. The solution of IMRALDI is clear and colorless, with a pH of about 5.2.

Each 40 mg/0.8 mL pre-filled pen delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of IMRALDI contains adalimumab (40 mg), trisodium citrate dihydrate (1.6 mg), citric acid monohydrate (0.544 mg), histidine (0.96 mg), histidine monohydrochloride monohydrate (8.64 mg), sorbitol (20.0 mg), polysorbate 20 (0.64 mg), and Water for Injection.

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyases surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis plaques. In Ps, treatment with adalimumab may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which adalimumab exerts its clinical effects is unknown.

Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10^{-10} M).

12.2 Pharmacodynamics
After treatment with adalimumab, a decrease in levels of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-6) was observed compared to baseline in patients with rheumatoid arthritis. A decrease in CRP levels was also observed in patients with Crohn's disease and ulcerative colitis. Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodeling responsible for cartilage destruction were also decreased after adalimumab administration.

12.3 Pharmacokinetics

The maximum serum concentration \( C_{\text{max}} \) and the time to reach the maximum concentration \( T_{\text{max}} \) were 4.7 ± 1.6 μg/mL and 131 ± 56 hours respectively, following a single 40 mg subcutaneous administration of adalimumab to healthy adult subjects. The average absolute bioavailability of adalimumab estimated from three studies following a single 40 mg subcutaneous dose was 64%. The pharmacokinetics of adalimumab were linear over the dose range of 0.5 to 10.0 mg/kg following a single intravenous dose.

The single dose pharmacokinetics of adalimumab in RA patients were determined in several studies with intravenous doses ranging from 0.25 to 10 mg/kg. The distribution volume \( V_{\text{ss}} \) ranged from 4.7 to 6.0 L. The systemic clearance of adalimumab is approximately 12 mL/hr. The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies. Adalimumab concentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to 96% of those in serum.

In RA patients receiving 40 mg adalimumab every other week, adalimumab mean steady-state trough concentrations of approximately 5 μg/mL and 8 to 9 μg/mL, were observed without and with methotrexate (MTX), respectively. MTX reduced adalimumab apparent clearance after single and multiple dosing by 29% and 44% respectively, in patients with RA. Mean serum adalimumab trough levels at steady state increased approximately proportionally with dose following 20, 40, and 80 mg every other week and every week subcutaneous dosing. In long-term studies with dosing more than two years, there was no evidence of changes in clearance over time.

Adalimumab mean steady-state trough concentrations were slightly higher in psoriatic arthritis patients treated with 40 mg adalimumab every other week (6 to 10 μg/mL and 8.5 to 12 μg/mL, without and with MTX, respectively) compared to the concentrations in RA patients treated with the same dose.

The pharmacokinetics of adalimumab in patients with AS were similar to those in patients with RA.

In patients with CD, the loading dose of 160 mg adalimumab on Week 0 followed by 80 mg adalimumab on Week 2 achieves mean serum adalimumab trough levels of approximately 12 μg/mL at Week 2 and Week 4. Mean steady-state trough levels of approximately 7 μg/mL were observed at Week 24 and Week 56 in CD patients after receiving a maintenance dose of 40 mg adalimumab every other week.

In patients with UC, the loading dose of 160 mg adalimumab on Week 0 followed by 80 mg adalimumab on Week 2 achieves mean serum adalimumab trough levels of approximately 12 μg/mL at Week 2 and Week 4. Mean steady-state trough level of approximately 8 μg/mL was observed at Week 52 in UC patients after receiving a dose of 40 mg adalimumab every other week, and approximately 15 μg/mL at Week 52 in UC patients who increased to a dose of 40 mg adalimumab every week.

In patients with Ps, the mean steady-state trough concentration was approximately 5 to 6 μg/mL during adalimumab 40 mg every other week monotherapy treatment.

Population pharmacokinetic analyses in patients with RA revealed that there was a trend toward higher apparent clearance of adalimumab in the presence of anti-adalimumab antibodies, and lower clearance with increasing age in patients aged 40 to >75 years.

Minor increases in apparent clearance were also predicted in RA patients receiving doses lower than the recommended dose and in RA patients with high rheumatoid factor or CRP concentrations. These increases are not likely to be clinically important.

No gender-related pharmacokinetic differences were observed after correction for a patient's body weight. Healthy volunteers and patients with rheumatoid arthritis displayed similar adalimumab
pharmacokinetics.

No pharmacokinetic data are available in patients with hepatic or renal impairment.

In Study JIA-I for patients with polyarticular JIA who were 4 to 17 years of age, the mean steady-state trough serum adalimumab concentrations for patients weighing <30 kg receiving 20 mg adalimumab subcutaneously every other week as monotherapy or with concomitant MTX were 6.8 μg/mL and 10.9 μg/mL, respectively. The mean steady-state trough serum adalimumab concentrations for patients weighing ≥30 kg receiving 40 mg adalimumab subcutaneously every other week as monotherapy or with concomitant MTX were 6.6 μg/mL and 8.1 μg/mL, respectively.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies of adalimumab have not been conducted to evaluate the carcinogenic potential or its effect on fertility.

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

The efficacy and safety of adalimumab were assessed in five randomized, double-blind studies in patients ≥18 years of age with active rheumatoid arthritis (RA) diagnosed according to American College of Rheumatology (ACR) criteria. Patients had at least 6 swollen and 9 tender joints. Adalimumab was administered subcutaneously in combination with methotrexate (MTX) (12.5 to 25 mg, Studies RA-I, RA-III and RA-V) or as monotherapy (Studies RA-II and RA-V) or with other disease-modifying anti-rheumatic drugs (DMARDs) (Study RA-IV).

Study RA-I evaluated 271 patients who had failed therapy with at least one but no more than four DMARDs and had inadequate response to MTX. Doses of 20, 40 or 80 mg of adalimumab or placebo were given every other week for 24 weeks.

Study RA-II evaluated 544 patients who had failed therapy with at least one DMARD. Doses of placebo, 20 or 40 mg of adalimumab were given as monotherapy every other week or weekly for 26 weeks.

Study RA-III evaluated 619 patients who had an inadequate response to MTX. Patients received placebo, 40 mg of adalimumab every other week with placebo injections on alternate weeks, or 20 mg of adalimumab weekly for up to 52 weeks. Study RA-III had an additional primary endpoint at 52 weeks of inhibition of disease progression (as detected by X-ray results). Upon completion of the first 52 weeks, 457 patients enrolled in an open-label extension phase in which 40 mg of adalimumab was administered every other week for up to 5 years.

Study RA-IV assessed safety in 636 patients who were either DMARD-naive or were permitted to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a minimum of 28 days. Patients were randomized to 40 mg of adalimumab or placebo every other week for 24 weeks.

Study RA-V evaluated 799 patients with moderately to severely active RA of less than 3 years duration who were ≥18 years old and MTX naïve. Patients were randomized to receive either MTX (optimized to 20 mg/week by week 8), adalimumab 40 mg every other week or adalimumab /MTX combination therapy for 104 weeks. Patients were evaluated for signs and symptoms, and for radiographic progression of joint damage. The median disease duration among patients enrolled in the study was 5 months. The median MTX dose achieved was 20 mg.

Clinical Response

The percent of adalimumab treated patients achieving ACR 20, 50 and 70 responses in Studies RA-II
and III are shown in Table 2.

Table 2. ACR Responses in Studies RA-II and RA-III (Percent of Patients)

<table>
<thead>
<tr>
<th>Response</th>
<th>Study RA-II Monotherapy (26 weeks)</th>
<th>Study RA-III Methotrexate Combination (24 and 52 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Adalimumab 40 mg every other week</td>
</tr>
<tr>
<td></td>
<td>N=110</td>
<td>N=113</td>
</tr>
<tr>
<td>ACR20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Month 6</td>
<td>19%</td>
<td>46%*</td>
</tr>
<tr>
<td>Month 12</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>ACR50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Month 6</td>
<td>8%</td>
<td>22%*</td>
</tr>
<tr>
<td>Month 12</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>ACR70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Month 6</td>
<td>2%</td>
<td>12%*</td>
</tr>
<tr>
<td>Month 12</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

* p<0.01, adalimumab vs. placebo

The results of Study RA-I were similar to Study RA-III; patients receiving adalimumab 40 mg every other week in Study RA-I also achieved ACR 20, 50 and 70 response rates of 65%, 52% and 24%, respectively, compared to placebo responses of 13%, 7% and 3% respectively, at 6 months (p<0.01).

The results of the components of the ACR response criteria for Studies RA-II and RA-III are shown in Table 3. ACR response rates and improvement in all components of ACR response were maintained to week 104. Over the 2 years in Study RA-III, 20% of adalimumab patients receiving 40 mg every other week (EOW) achieved a major clinical response, defined as maintenance of an ACR 70 response over a 6-month period. ACR responses were maintained in similar proportions of patients for up to 5 years with continuous adalimumab treatment in the open-label portion of Study RA-III.

Table 3. Components of ACR Response in Studies RA-II and RA-III

<table>
<thead>
<tr>
<th>Parameter (median)</th>
<th>Study RA-II</th>
<th>Study RA-III</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo N=110</td>
<td>Adalimumab^a N=113</td>
</tr>
<tr>
<td></td>
<td>Baseline Wk 26</td>
<td>Baseline Wk 26</td>
</tr>
<tr>
<td>Number of tender joints (0-68)</td>
<td>35  26</td>
<td>31  16^*</td>
</tr>
<tr>
<td>Number of swollen joints (0-66)</td>
<td>19  16</td>
<td>18  10^*</td>
</tr>
<tr>
<td>Physician global assessment^b</td>
<td>7.0  6.1</td>
<td>6.6  3.7^*</td>
</tr>
<tr>
<td>Patient global assessment^b</td>
<td>7.5  6.3</td>
<td>7.5  4.5^*</td>
</tr>
<tr>
<td>Pain^b</td>
<td>7.3  6.1</td>
<td>7.3  4.1^*</td>
</tr>
<tr>
<td>Disability index</td>
<td>2.0  1.9</td>
<td>1.9  1.5^*</td>
</tr>
</tbody>
</table>
40 mg adalimumab administered every other week

Visual analogue scale; 0 = best, 10 = worst

Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the patient's ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity

p<0.001, adalimumab vs. placebo, based on mean change from baseline

The time course of ACR 20 response for Study RA-III is shown in Figure 1.

In Study RA-III, 85% of patients with ACR 20 responses at week 24 maintained the response at 52 weeks. The time course of ACR 20 response for Study RA-I and Study RA-II were similar.

Figure 1. Study RA-III ACR 20 Responses over 52 Weeks

In Study RA-IV, 53% of patients treated with adalimumab 40 mg every other week plus standard of care had an ACR 20 response at week 24 compared to 35% on placebo plus standard of care (p<0.001). No unique adverse reactions related to the combination of adalimumab and other DMARDs were observed.

In Study RA-V with MTX naïve patients with recent onset RA, the combination treatment with adalimumab plus MTX led to greater percentages of patients achieving ACR responses than either MTX monotherapy or adalimumab monotherapy at Week 52 and responses were sustained at Week 104 (see Table 4).

Table 4. ACR Response in Study RA-V (Percent of Patients)

<table>
<thead>
<tr>
<th>Response</th>
<th>MTX&lt;sup&gt;b&lt;/sup&gt; N=257</th>
<th>Adalimumab&lt;sup&gt;c&lt;/sup&gt; N=274</th>
<th>Adalimumab/MTX N=268</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 52</td>
<td>63%</td>
<td>54%</td>
<td>73%</td>
</tr>
<tr>
<td>Week 104</td>
<td>56%</td>
<td>49%</td>
<td>69%</td>
</tr>
<tr>
<td>ACR50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 52</td>
<td>46%</td>
<td>41%</td>
<td>62%</td>
</tr>
<tr>
<td>Week 104</td>
<td>43%</td>
<td>37%</td>
<td>59%</td>
</tr>
<tr>
<td>ACR70</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 52</td>
<td>27%</td>
<td>26%</td>
<td>46%</td>
</tr>
<tr>
<td>Week 104</td>
<td>28%</td>
<td>28%</td>
<td>47%</td>
</tr>
</tbody>
</table>
Major clinical response is defined as achieving an ACR70 response for a continuous six month period. 

p<0.05, adalimumab/MTX vs. MTX for ACR 20 

p<0.001, adalimumab/MTX vs. MTX for ACR 50 and 70, and Major Clinical Response 

p<0.001, adalimumab/MTX vs. adalimumab

At Week 52, all individual components of the ACR response criteria for Study RA-V improved in the adalimumab/MTX group and improvements were maintained to Week 104.

Radiographic Response

In Study RA-III, structural joint damage was assessed radiographically and expressed as change in Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score, at month 12 compared to baseline. At baseline, the median TSS was approximately 55 in the placebo and 40 mg every other week groups. The results are shown in Table 5. Adalimumab/MTX treated patients demonstrated less radiographic progression than patients receiving MTX alone at 52 weeks.

Table 5. Radiographic Mean Changes Over 12 Months in Study RA-III

<table>
<thead>
<tr>
<th></th>
<th>Placebo/MTX</th>
<th>Adalimumab/MTX 40 mg every other week</th>
<th>Placebo/MTX-adalimumab/MTX (95% Confidence Interval*)</th>
<th>P-value**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Sharp score</td>
<td>2.7</td>
<td>0.1</td>
<td>2.6 (1.4, 3.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Erosion score</td>
<td>1.6</td>
<td>0.0</td>
<td>1.6 (0.9, 2.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>JSN score</td>
<td>1.0</td>
<td>0.1</td>
<td>0.9 (0.3, 1.4)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

* 95% confidence intervals for the differences in change scores between MTX and adalimumab. 
** Based on rank analysis

In the open-label extension of Study RA-III, 77% of the original patients treated with any dose of adalimumab were evaluated radiographically at 2 years. Patients maintained inhibition of structural damage, as measured by the TSS. Fifty-four percent had no progression of structural damage as defined by a change in the TSS of zero or less. Fifty-five percent (55%) of patients originally treated with 40 mg adalimumab every other week have been evaluated radiographically at 5 years. Patients had continued inhibition of structural damage with 50% showing no progression of structural damage defined by a change in the TSS of zero or less.

In Study RA-V, structural joint damage was assessed as in Study RA-III. Greater inhibition of radiographic progression, as assessed by changes in TSS, erosion score and JSN was observed in the adalimumab/MTX combination group as compared to either the MTX or adalimumab monotherapy group at Week 52 as well as at Week 104 (see Table 6).

Table 6. Radiographic Mean Change* in Study RA-V

<table>
<thead>
<tr>
<th></th>
<th>MTX* N=257</th>
<th>Adalimumab* N=274</th>
<th>Adalimumab/MTX N=268</th>
</tr>
</thead>
<tbody>
<tr>
<td>52 Weeks Total Sharp score</td>
<td>5.7 (4.2, 7.3)</td>
<td>3.0 (1.7, 4.3)</td>
<td>1.3 (0.5, 2.1)</td>
</tr>
<tr>
<td>Erosion score</td>
<td>3.7 (2.7, 4.8)</td>
<td>1.7 (1.0, 2.4)</td>
<td>0.8 (0.4, 1.2)</td>
</tr>
<tr>
<td>JSN score</td>
<td>2.0 (1.2, 2.8)</td>
<td>1.3 (0.5, 2.1)</td>
<td>0.5 (0.0, 1.0)</td>
</tr>
<tr>
<td>104 Weeks Total Sharp score</td>
<td>10.4 (7.7, 13.2)</td>
<td>5.5 (3.6, 7.4)</td>
<td>1.9 (0.9, 2.9)</td>
</tr>
<tr>
<td>Erosion score</td>
<td>6.4 (4.6, 8.2)</td>
<td>3.0 (2.0, 4.0)</td>
<td>1.0 (0.4, 1.6)</td>
</tr>
</tbody>
</table>
### Physical Function Response

In studies RA-I through IV, adalimumab showed significantly greater improvement than placebo in the disability index of Health Assessment Questionnaire (HAQ-DI) from baseline to the end of study, and significantly greater improvement than placebo in the health-outcomes as assessed by The Short Form Health Survey (SF 36). Improvement was seen in both the Physical Component Summary (PCS) and the Mental Component Summary (MCS).

In Study RA-III, the mean (95% CI) improvement in HAQ-DI from baseline at week 52 was 0.60 (0.55, 0.65) for the adalimumab patients and 0.25 (0.17, 0.33) for placebo/MTX (p<0.001) patients. Sixty-three percent of adalimumab-treated patients achieved a 0.5 or greater improvement in HAQ-DI at week 52 in the double-blind portion of the study. Eighty-two percent of these patients maintained that improvement through week 104 and a similar proportion of patients maintained this response through week 260 (5 years) of open-label treatment. Mean improvement in the SF-36 was maintained through the end of measurement at week 156 (3 years).

In Study RA-V, the HAQ-DI and the physical component of the SF-36 showed greater improvement (p<0.001) for the adalimumab/MTX combination therapy group versus either the MTX monotherapy or the adalimumab monotherapy group at Week 52, which was maintained through Week 104.

### 14.2 Juvenile Idiopathic Arthritis

The safety and efficacy of adalimumab was assessed in a study (Study JIA-I) in patients with active polyarticular juvenile idiopathic arthritis (JIA).

**Study JIA-I**

The safety and efficacy of adalimumab were assessed in a multicenter, randomized, withdrawal, double-blind, parallel-group study in 171 patients who were 4 to 17 years of age with polyarticular JIA. In the study, the patients were stratified into two groups: MTX-treated or non-MTX-treated. All patients had to show signs of active moderate or severe disease despite previous treatment with NSAIDs, analgesics, corticosteroids, or DMARDS. Patients who received prior treatment with any biologic DMARDS were excluded from the study.

The study included four phases: an open-label lead-in phase (OL-LI; 16 weeks), a double-blind randomized withdrawal phase (DB; 32 weeks), an open-label extension phase (OLE-BSA; up to 136 weeks), and an open-label fixed-dose phase (OLE-FD; 16 weeks). In the first three phases of the study, adalimumab was administered based on body surface area at a dose of 24 mg/m² up to a maximum total body dose of 40 mg subcutaneously (SC) every other week. In the OLE-FD phase, the patients were treated with 20 mg of adalimumab SC every other week if their weight was less than 30 kg and with 40 mg of adalimumab SC every other week if their weight was 30 kg or greater. Patients remained on stable doses of NSAIDs and/or prednisone (≤0.2 mg/kg/day or 10 mg/day maximum).

Patients demonstrating a Pediatric ACR 30 response at the end of OL-LI phase were randomized into the double-blind (DB) phase of the study and received either adalimumab or placebo every other week for 32 weeks or until disease flare. Disease flare was defined as a worsening of ≥30% from baseline in ≥3 of 6 Pediatric ACR core criteria, ≥2 active joints, and improvement of ≥30% in no more than 1 of the 6 criteria. After 32 weeks or at the time of disease flare during the DB phase, patients were treated in the open-label extension phase based on the BSA regimen (OLE-BSA), before converting to a fixed dose regimen based on body weight (OLE-FD phase).

**Study JIA-I Clinical Response**
At the end of the 16-week OL-LI phase, 94% of the patients in the MTX stratum and 74% of the patients in the non-MTX stratum were Pediatric ACR 30 responders. In the DB phase significantly fewer patients who received adalimumab experienced disease flare compared to placebo, both without MTX (43% vs. 71%) and with MTX (37% vs. 65%). More patients treated with adalimumab continued to show pediatric ACR 30/50/70 responses at Week 48 compared to patients treated with placebo. Pediatric ACR responses were maintained for up to two years in the OLE phase in patients who received adalimumab throughout the study.

14.3 Psoriatic Arthritis

The safety and efficacy of adalimumab was assessed in two randomized, double-blind, placebo controlled studies in 413 patients with psoriatic arthritis (PsA). Upon completion of both studies, 383 patients enrolled in an open-label extension study, in which 40 mg adalimumab was administered every other week.

Study PsA-I enrolled 313 adult patients with moderately to severely active PsA (>3 swollen and >3 tender joints) who had an inadequate response to NSAID therapy in one of the following forms: (1) distal interphalangeal (DIP) involvement (N=23); (2) polyarticular arthritis (absence of rheumatoid nodules and presence of plaque psoriasis) (N=210); (3) arthritis mutilans (N=1); (4) asymmetric PsA (N=77); or (5) AS-like (N=2). Patients on MTX therapy (158 of 313 patients) at enrollment (stable dose of ≤30 mg/week for >1 month) could continue MTX at the same dose. Doses of adalimumab 40 mg or placebo every other week were administered during the 24-week double-blind period of the study.

Compared to placebo, treatment with adalimumab resulted in improvements in the measures of disease activity (see Tables 7 and 8). Among patients with PsA who received adalimumab, the clinical responses were apparent in some patients at the time of the first visit (two weeks) and were maintained up to 88 weeks in the ongoing open-label study. Similar responses were seen in patients with each of the subtypes of psoriatic arthritis, although few patients were enrolled with the arthritis mutilans and ankylosing spondylitis-like subtypes. Responses were similar in patients who were or were not receiving concomitant MTX therapy at baseline.

Patients with psoriatic involvement of at least three percent body surface area (BSA) were evaluated for Psoriatic Area and Severity Index (PASI) responses. At 24 weeks, the proportions of patients achieving a 75% or 90% improvement in the PASI were 59% and 42% respectively, in the adalimumab group (N=69), compared to 1% and 0% respectively, in the placebo group (N=69) (p<0.001). PASI responses were apparent in some patients at the time of the first visit (two weeks). Responses were similar in patients who were or were not receiving concomitant MTX therapy at baseline.

### Table 7. ACR Response in Study PsA-I (Percent of Patients)

<table>
<thead>
<tr>
<th></th>
<th>Placebo N=162</th>
<th>Adalimumab* N=151</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACR20</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 12</td>
<td>14%</td>
<td>58%</td>
</tr>
<tr>
<td>Week 24</td>
<td>15%</td>
<td>57%</td>
</tr>
<tr>
<td><strong>ACR50</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 12</td>
<td>4%</td>
<td>36%</td>
</tr>
<tr>
<td>Week 24</td>
<td>6%</td>
<td>39%</td>
</tr>
<tr>
<td><strong>ACR70</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 12</td>
<td>1%</td>
<td>20%</td>
</tr>
<tr>
<td>Week 24</td>
<td>1%</td>
<td>23%</td>
</tr>
</tbody>
</table>

* p<0.001 for all comparisons between adalimumab and placebo

### Table 8. Components of Disease Activity in Study PsA-I
Similar results were seen in an additional, 12-week study in 100 patients with moderate to severe psoriatic arthritis who had suboptimal response to DMARD therapy as manifested by ≥3 tender joints and ≥3 swollen joints at enrollment.

**Radiographic Response**

Radiographic changes were assessed in the PsA studies. Radiographs of hands, wrists, and feet were obtained at baseline and Week 24 during the double-blind period when patients were on adalimumab or placebo and at Week 48 when all patients were on open-label adalimumab. A modified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e., not identical to the TSS used for rheumatoid arthritis), was used by readers blinded to treatment group to assess the radiographs.

Adalimumab-treated patients demonstrated greater inhibition of radiographic progression compared to placebo-treated patients and this effect was maintained at 48 weeks (see Table 9).

**Table 9. Change in Modified Total Sharp Score in Psoriatic Arthritis**

<table>
<thead>
<tr>
<th></th>
<th>Placebo N=141</th>
<th>Adalimumab N=133</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline mean</td>
<td>Week 24</td>
<td>Week 24</td>
</tr>
<tr>
<td>Mean Change ± SD</td>
<td>0.9 ± 3.1</td>
<td>-0.1 ± 1.7</td>
</tr>
</tbody>
</table>

*p<0.001 for the difference between adalimumab, Week 48 and Placebo, Week 24 (primary analysis)*

**Physical Function Response**

In Study PsA-I, physical function and disability were assessed using the HAQ Disability Index (HAQ-DI) and the SF-36 Health Survey. Patients treated with 40 mg of adalimumab every other week showed greater improvement from baseline in the HAQ-DI score (mean decreases of 47% and 49% at Weeks 12 and 24 respectively) in comparison to placebo (mean decreases of 1% and 3% at Weeks 12 and 24 respectively). At Weeks 12 and 24, patients treated with adalimumab showed greater improvement from baseline in the SF-36 Physical Component Summary score compared to patients treated with placebo, and no worsening in the SF-36 Mental Component Summary score. Improvement in physical function based on the HAQ-DI was maintained for up to 84 weeks through the open-label portion of the study.

**14.4 Ankylosing Spondylitis**
The safety and efficacy of adalimumab 40 mg every other week was assessed in 315 adult patients in a randomized, 24 week double-blind, placebo-controlled study in patients with active ankylosing spondylitis (AS) who had an inadequate response to glucocorticoids, NSAIDs, analgesics, methotrexate or sulfasalazine. Active AS was defined as patients who fulfilled at least two of the following three criteria: (1) a Bath AS disease activity index (BASDAI) score ≥4 cm, (2) a visual analog score (VAS) for total back pain ≥ 40 mm, and (3) morning stiffness ≥ 1 hour. The blinded period was followed by an open-label period during which patients received adalimumab 40 mg every other week subcutaneously for up to an additional 28 weeks.

Improvement in measures of disease activity was first observed at Week 2 and maintained through 24 weeks as shown in Figure 2 and Table 10.

Responses of patients with total spinal ankylosis (n=11) were similar to those without total ankylosis.

At 12 weeks, the ASAS 20/50/70 responses were achieved by 58%, 38%, and 23%, respectively, of patients receiving adalimumab, compared to 21%, 10%, and 5% respectively, of patients receiving placebo (p <0.001). Similar responses were seen at Week 24 and were sustained in patients receiving open-label adalimumab for up to 52 weeks.

A greater proportion of patients treated with adalimumab (22%) achieved a low level of disease activity at 24 weeks (defined as a value <20 [on a scale of 0 to 100 mm] in each of the four ASAS response parameters) compared to patients treated with placebo (6%).

Table 10. Components of Ankylosing Spondylitis Disease Activity

<table>
<thead>
<tr>
<th></th>
<th>Placebo N=107</th>
<th>Adalimumab N=208</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline mean</td>
<td>Week 24 mean</td>
</tr>
<tr>
<td>ASAS 20 Response Criteria*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient’s Global Assessment of Disease Activitya*</td>
<td>65</td>
<td>60</td>
</tr>
<tr>
<td>Total back pain*</td>
<td>67</td>
<td>58</td>
</tr>
<tr>
<td>Inflammationb*</td>
<td>6.7</td>
<td>5.6</td>
</tr>
</tbody>
</table>
A second randomized, multicenter, double-blind, placebo-controlled study of 82 patients with ankylosing spondylitis showed similar results. Patients treated with adalimumab achieved improvement from baseline in the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) score (-3.6 vs. -1.1) and in the Short Form Health Survey (SF-36) Physical Component Summary (PCS) score (7.4 vs. 1.9) compared to placebo-treated patients at Week 24.

### 14.5 Adult Crohn's Disease

The safety and efficacy of multiple doses of adalimumab were assessed in adult patients with moderately to severely active Crohn's disease, CD, (Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450) in randomized, double-blind, placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted, and 79% of patients continued to receive at least one of these medications.

Induction of clinical remission (defined as CDAI < 150) was evaluated in two studies. In Study CD-I, 299 TNF-blocker naïve patients were randomized to one of four treatment groups: the placebo group received placebo at Weeks 0 and 2, the 160/80 group received 160 mg adalimumab at Week 0 and 80 mg at Week 2, the 80/40 group received 80 mg at Week 0 and 40 mg at Week 2, and the 40/20 group received 40 mg at Week 0 and 20 mg at Week 2. Clinical results were assessed at Week 4.

In the second induction study, Study CD-II, 325 patients who had lost response to, or were intolerant to, previous infliximab therapy were randomized to receive either 160 mg adalimumab at Week 0 and 80 mg at Week 2, or placebo at Weeks 0 and 2. Clinical results were assessed at Week 4.

Maintenance of clinical remission was evaluated in Study CD-III. In this study, 854 patients with active disease received open-label adalimumab, 80 mg at week 0 and 40 mg at Week 2. Patients were then randomized at Week 4 to 40 mg adalimumab every other week, 40 mg adalimumab every week, or placebo. The total study duration was 56 weeks. Patients in clinical response (decrease in CDAI ≥70) at Week 4 were stratified and analyzed separately from those not in clinical response at Week 4.

**Induction of Clinical Remission**

A greater percentage of the patients treated with 160/80 mg adalimumab achieved induction of clinical remission versus placebo at Week 4 regardless of whether the patients were TNF blocker naïve (CD-I), or had lost response to or were intolerant to infliximab (CD-II) (see Table 11).
Table 11. Induction of Clinical Remission in Studies CD-I and CD-II (Percent of Patients)

<table>
<thead>
<tr>
<th></th>
<th>CD-I</th>
<th>CD-II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo N=74</td>
<td>Adalimumab 160/80 mg N=76</td>
</tr>
<tr>
<td>Week 4</td>
<td>Clinical remission 12%</td>
<td>36%*</td>
</tr>
<tr>
<td></td>
<td>Clinical response 34%</td>
<td>58%**</td>
</tr>
</tbody>
</table>

Clinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 points.

* p<0.001 for adalimumab vs. placebo pairwise comparison of proportions
** p<0.01 for adalimumab vs. placebo pairwise comparison of proportions

Maintenance of Clinical Remission

In Study CD-III at Week 4, 58% (499/854) of patients were in clinical response and were assessed in the primary analysis. At Weeks 26 and 56, greater proportions of patients who were in clinical response at Week 4 achieved clinical remission in the adalimumab 40 mg every other week maintenance group compared to patients in the placebo maintenance group (see Table 12). The group that received adalimumab therapy every week did not demonstrate significantly higher remission rates compared to the group that received adalimumab every other week.

Table 12. Maintenance of Clinical Remission in CD-III (Percent of Patients)

<table>
<thead>
<tr>
<th></th>
<th>Placebo N=170</th>
<th>40 mg adalimumab every other week N=172</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 26</td>
<td>Clinical remission 17%</td>
<td>40%*</td>
</tr>
<tr>
<td></td>
<td>Clinical response 28%</td>
<td>54%*</td>
</tr>
<tr>
<td>Week 56</td>
<td>Clinical remission 12%</td>
<td>36%*</td>
</tr>
<tr>
<td></td>
<td>Clinical response 18%</td>
<td>43%*</td>
</tr>
</tbody>
</table>

Clinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 points.

* p<0.001 for adalimumab vs. placebo pairwise comparisons of proportions

Of those in response at Week 4 who attained remission during the study, patients in the adalimumab every other week group maintained remission for a longer time than patients in the placebo maintenance group. Among patients who were not in response by Week 12, therapy continued beyond 12 weeks did not result in significantly more responses.

14.6 Ulcerative Colitis

The safety and efficacy of adalimumab were assessed in adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12 on a 12 point scale, with an endoscopy subscore of 2 to 3 on a scale of 0 to 3) despite concurrent or prior treatment with immunosuppressants such as corticosteroids, azathioprine, or 6-MP in two randomized, double-blind, placebo-controlled clinical studies (Studies UC-I and UC-II). Both studies enrolled TNF-blocker naïve patients, but Study UC-II also allowed entry of patients who lost response to or were intolerant to TNF-blockers. Forty percent (40%) of patients enrolled in Study UC-II had previously used another TNF-blocker.

Concomitant stable doses of aminosalicylates and immunosuppressants were permitted. In Studies UC-I and II, patients were receiving aminosalicylates (69%), corticosteroids (59%) and/or azathioprine or 6-MP (37%) at baseline. In both studies, 92% of patients received at least one of these medications.
Induction of clinical remission (defined as Mayo score ≤ 2 with no individual subscores > 1) at Week 8 was evaluated in both studies. Clinical remission at Week 52 and sustained clinical remission (defined as clinical remission at both Weeks 8 and 52) were evaluated in Study UC-II.

In Study UC-I, 390 TNF-blocker naïve patients were randomized to one of three treatment groups for the primary efficacy analysis. The placebo group received placebo at Weeks 0, 2, 4 and 6. The 160/80 group received 160 mg adalimumab at Week 0 and 80 mg at Week 2, and the 80/40 group received 80 mg adalimumab at Week 0 and 40 mg at Week 2. After Week 2, patients in both adalimumab treatment groups received 40 mg every other week (eow).

In Study UC-II, 518 patients were randomized to receive either adalimumab 160 mg at Week 0, 80 mg at Week 2, and 40 mg eow starting at Week 4 through Week 50, or placebo starting at Week 0 and eow through Week 50. Corticosteroid taper was permitted starting at Week 8.

In both Studies UC-I and UC-II, a greater percentage of the patients treated with 160/80 mg of adalimumab compared to patients treated with placebo achieved induction of clinical remission. In Study UC-II, a greater percentage of the patients treated with 160/80 mg of adalimumab compared to patients treated with placebo achieved sustained clinical remission (clinical remission at both Weeks 8 and 52) (Table 14).

**Table 14. Induction of Clinical Remission in Studies UC-I and UC-II and Sustained Clinical Remission in Study UC-II (Percent of Patients)**

<table>
<thead>
<tr>
<th></th>
<th>Study UC-I</th>
<th>Study UC-II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo N=130</td>
<td>Adalimumab 160/80 mg N=130</td>
</tr>
<tr>
<td>Induction of Clinical Remission (Clinical Remission at Week 8)</td>
<td>9.2%</td>
<td>18.5%</td>
</tr>
<tr>
<td>Sustained Clinical Remission (Clinical Remission at both Weeks 8 and 52)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Clinical remission is defined as Mayo score ≤ 2 with no individual subscores > 1.
CI=Confidence interval
* p<0.05 for adalimumab vs. placebo pairwise comparison of proportions

In Study UC-I, there was no statistically significant difference in clinical remission observed between the adalimumab 80/40 mg group and the placebo group at Week 8.

In Study UC-II, 17.3% (43/248) in the adalimumab group were in clinical remission at Week 52 compared to 8.5% (21/246) in the placebo group (treatment difference: 8.8%; 95% confidence interval (CI): [2.8%, 14.5%]; p<0.05).

In the subgroup of patients in Study UC-II with prior TNF-blocker use, the treatment difference for induction of clinical remission appeared to be lower than that seen in the whole study population, and the treatment differences for sustained clinical remission and clinical remission at Week 52 appeared to be similar to those seen in the whole study population. The subgroup of patients with prior TNF-blocker use achieved induction of clinical remission at 9% (9/98) in the adalimumab group versus 7% (7/101) in the placebo group, and sustained clinical remission at 5% (5/98) in the adalimumab group versus 1% (1/101) in the placebo group. In the subgroup of patients with prior TNF-blocker use, 10%
were in clinical remission at Week 52 in the adalimumab group versus 3% (3/101) in the placebo group.

14.7 Plaque Psoriasis

The safety and efficacy of adalimumab were assessed in randomized, double-blind, placebo-controlled studies in 1696 adult subjects with moderate to severe chronic plaque psoriasis (Ps) who were candidates for systemic therapy or phototherapy.

Study Ps-I evaluated 1212 subjects with chronic Ps with ≥10% body surface area (BSA) involvement, Physician's Global Assessment (PGA) of at least moderate disease severity, and Psoriasis Area and Severity Index (PASI) ≥12 within three treatment periods. In period A, subjects received placebo or adalimumab at an initial dose of 80 mg at Week 0 followed by a dose of 40 mg every other week starting at Week 1. After 16 weeks of therapy, subjects who achieved at least a PASI 75 response at Week 16, defined as a PASI score improvement of at least 75% relative to baseline, entered period B and received open-label 40 mg adalimumab every other week. After 17 weeks of open label therapy, subjects who maintained at least a PASI 75 response at Week 33 and were originally randomized to active therapy in period A were re-randomized in period C to receive 40 mg adalimumab every other week or placebo for an additional 19 weeks. Across all treatment groups the mean baseline PASI score was 19 and the baseline Physician's Global Assessment score ranged from “moderate” (53%) to “severe” (41%) to “very severe” (6%).

Study Ps-II evaluated 99 subjects randomized to adalimumab and 48 subjects randomized to placebo with chronic plaque psoriasis with ≥10% BSA involvement and PASI ≥12. Subjects received placebo, or an initial dose of 80 mg adalimumab at Week 0 followed by 40 mg every other week starting at Week 1 for 16 weeks. Across all treatment groups the mean baseline PASI score was 21 and the baseline PGA score ranged from “moderate” (41%) to “severe” (51%) to “very severe” (8%).

Studies Ps-I and II evaluated the proportion of subjects who achieved “clear” or “minimal” disease on the 6-point PGA scale and the proportion of subjects who achieved a reduction in PASI score of at least 75% (PASI 75) from baseline at Week 16 (see Table 15 and 16).

Additionally, Study Ps-I evaluated the proportion of subjects who maintained a PGA of “clear” or “minimal” disease or a PASI 75 response after Week 33 and on or before Week 52.

### Table 15. Efficacy Results at 16 Weeks in Study Ps-I Number of Subjects (%)

<table>
<thead>
<tr>
<th></th>
<th>Adalimumab 40 mg every other week</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGA: Clear or minimal*</td>
<td>506 (62%)</td>
<td>17 (4%)</td>
</tr>
<tr>
<td>PASI 75</td>
<td>578 (71%)</td>
<td>26 (7%)</td>
</tr>
</tbody>
</table>

* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red coloration

Minimal = possible but difficult to ascertain whether there is slight elevation of plaque above normal skin, plus or minus surface dryness with some white coloration, plus or minus up to red coloration

### Table 16. Efficacy Results at 16 Weeks in Study Ps-II Number of Subjects (%)

<table>
<thead>
<tr>
<th></th>
<th>Adalimumab 40 mg every other week</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGA: Clear or minimal*</td>
<td>70 (71%)</td>
<td>5 (10%)</td>
</tr>
<tr>
<td>PASI 75</td>
<td>77 (78%)</td>
<td>9 (19%)</td>
</tr>
</tbody>
</table>

* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red coloration

Minimal = possible but difficult to ascertain whether there is slight elevation of plaque above normal skin, plus or minus surface dryness with some white coloration, plus or minus up to red coloration
Additionally, in Study Ps-I, subjects on adalimumab who maintained a PASI 75 were re-randomized to adalimumab (N = 250) or placebo (N = 240) at Week 33. After 52 weeks of treatment with adalimumab, more subjects on adalimumab maintained efficacy when compared to subjects who were re-randomized to placebo based on maintenance of PGA of “clear” or “minimal” disease (68% vs. 28%) or a PASI 75 (79% vs. 43%).

A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label extension study. Median time to relapse (decline to PGA “moderate” or worse) was approximately 5 months. During the withdrawal period, no subject experienced transformation to either pustular or erythrodermic psoriasis. A total of 178 subjects who relapsed re-initiated treatment with 80 mg of adalimumab, then 40 mg eow beginning at week 1. At week 16, 69% (123/178) of subjects had a response of PGA “clear” or “minimal”.

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING
IMRALDI (adalimumab-xxxx) is supplied as a preservative-free, sterile solution for subcutaneous administration. The following packaging configurations are available.

- **IMRALDI Pre-filled Pen Carton - 40 mg/0.8 mL**
  IMRALDI is dispensed in a carton containing two dose packs, one package insert, one Medication Guide, and one Instructions for Use. Each pack consists of a single-dose pre-filled pen, containing a 1 mL pre-filled glass syringe with a fixed 29 gauge, ½ inch needle, providing 40 mg/0.8 mL of IMRALDI. The NDC number is 71202-002-02.

Storage and Stability
Do not use beyond the expiration date on the container. IMRALDI must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE. Do not use if frozen even if it has been thawed.

Store in original carton until time of administration to protect from light.

If needed, for example when traveling, IMRALDI may be stored at room temperature up to a maximum of 77°F (25°C) for a period of up to 14 days, with protection from light. IMRALDI should be discarded if not used within the 14-day period.

Do not store IMRALDI in extreme heat or cold.

17 PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Medication Guide and Instructions for Use).

Patient Counseling

Provide the IMRALDI “Medication Guide” to patients or their caregivers, and provide them an opportunity to read it and ask questions prior to initiation of therapy and prior to each time the prescription is renewed. If patients develop signs and symptoms of infection, instruct them to seek medical evaluation immediately.

Advise patients of the potential benefits and risks of IMRALDI.

- **Infections**
  Inform patients that IMRALDI may lower the ability of their immune system to fight infections. Instruct patients of the importance of contacting their doctor if they develop any symptoms of
infection, including tuberculosis, invasive fungal infections, and reactivation of hepatitis B virus infections.

- **Malignancies**
  Counsel patients about the risk of malignancies while receiving IMRALDI.

- **Allergic Reactions**
  Advise patients to seek immediate medical attention if they experience any symptoms of severe allergic reactions.

- **Other Medical Conditions**
  Advise patients to report any signs of new or worsening medical conditions such as congestive heart failure, neurological disease, autoimmune disorders, or cytopenias. Advise patients to report any symptoms suggestive of a cytopenia such as bruising, bleeding, or persistent fever.

*Instructions on Injection Technique*

Inform patients that the first injection is to be performed under the supervision of a qualified health care professional. If a patient or caregiver is to administer IMRALDI, instruct them in injection techniques and assess their ability to inject subcutaneously to ensure the proper administration of IMRALDI [see Instructions for Use].

For patients who will use the IMRALDI Pre-filled Pen, tell them that they:
- May hear a 1st click when they place the red base straight on their skin and push the entire pen down firmly. The click means the start of the injection.
- Must keep holding the IMRALDI Pre-filled Pen against their skin until all of the medicine is injected.
- Will know that the injection has finished when the yellow indicator fills the medication window and stops moving. Also they may hear a 2nd click several seconds after starting the injection.

Instruct patients to dispose of their used pre-filled pen in a FDA-cleared sharps disposal container immediately after use. **Instruct patients not to dispose of pre-filled pen in their household trash.**

Instruct patients that if they do not have a FDA-cleared sharps disposal container, they may use a household container that is made of a heavy-duty plastic, can be closed with a tight-fitting and puncture-resistant lid without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container.

Instruct patients that when their sharps disposal container is almost full, they will need to follow their community guidelines for the correct way to dispose of their sharps disposal container. Instruct patients that there may be state or local laws regarding disposal of used pen. Refer patients to the FDA’s website at http://www.fda.gov/safesharpsdisposal for more information about safe sharps disposal, and for specific information about sharps disposal in the state that they live in.

**Instruct patients not to dispose of their used sharps disposal container in their household trash unless their community guidelines permit this. Instruct patients not to recycle their used sharps disposal container.**

**Manufactured by:** Samsung Bioepis Co., Ltd., 107, Cheomdan-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea

**U.S. License No. 2046**

**Manufactured for:** Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ 07033 USA
MEDICATION GUIDE
IMRALDI (Im-RAL-di)
(adalimumab-xxxx)
injection

Read the Medication Guide that comes with IMRALDI before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment.

**What is the most important information I should know about IMRALDI?**
IMRALDI is a medicine that affects your immune system. IMRALDI can lower the ability of your immune system to fight infections. **Serious infections have happened in people taking TNF blockers including adalimumab products. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi or bacteria that have spread throughout the body. Some people have died from these infections.**
- Your doctor should test you for TB before starting IMRALDI.
- Your doctor should check you closely for signs and symptoms of TB during treatment with IMRALDI.

You should not start taking IMRALDI if you have any kind of infection unless your doctor says it is okay.

**Before starting IMRALDI, tell your doctor if you:**
- think you have an infection or have symptoms of infection such as:
  - fever, sweats, or chills
  - muscle aches
  - cough
  - shortness of breath
  - blood in phlegm
  - warm, red, or painful skin or sores on your body
  - diarrhea or stomach pain
  - burning when you urinate or urinate more often than normal
  - feel very tired
  - weight loss
  - are being treated for an infection
  - get a lot of infections or have infections that keep coming back
  - have diabetes
  - have TB, or have been in close contact with someone with TB
  - were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your doctor if you are not sure.
  - live or have lived in certain parts of the country (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may happen or become more severe if you use IMRALDI. Ask your doctor if you do not know if you have lived in an area where these infections are common.
  - have or have had hepatitis B
  - use the medicine ORENCIA® (abatacept), KINERET® (anakinra), RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (6-mercaptopurine, 6-MP).
  - are scheduled to have major surgery

**After starting IMRALDI, call your doctor right away** if you have an infection, or any sign of an infection.
IMRALDI can make you more likely to get infections or make any infection that you may have worse.

**Cancer**
- For children and adults taking TNF-blockers, including adalimumab products, the chances of getting...
cancer may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF-blockers. People with RA, especially more serious RA, may have a higher chance for getting a kind of cancer called lymphoma. If you use TNF blockers including adalimumab product your chance of getting two types of skin cancer may increase (basal cell cancer and squamous cell cancer of the skin). These types of cancer are generally not life-threatening if treated. Tell your doctor if you have a bump or open sore that doesn't heal. Some people receiving TNF blockers including adalimumab products developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. Most of these people were male teenagers or young men. Also, most people were being treated for Crohn's disease or ulcerative colitis with another medicine called IMURAN® (azathioprine) or PURINETHOL® (6-mercaptopurine, 6–MP).

What is IMRALDI?
IMRALDI is a medicine called a Tumor Necrosis Factor (TNF) blocker. IMRALDI is used:

- To reduce the signs and symptoms of:
  - **moderate to severe rheumatoid arthritis (RA) in adults.** IMRALDI can be used alone, with methotrexate, or with certain other medicines.
  - **moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children** from 4 years of age and ≥ 30 kg (66 lbs). IMRALDI can be used alone, with methotrexate, or with certain other medicines.
  - **psoriatic arthritis (PsA) in adults.** IMRALDI can be used alone or with certain other medicines.
  - **ankylosing spondylitis (AS) in adults.**
  - **moderate to severe Crohn's disease (CD) in adults** when other treatments have not worked well enough.

In adults, to help get **moderate to severe ulcerative colitis (UC)** under control (induce remission) and keep it under control (sustain remission) when certain other medicines have not worked well enough. It is not known if IMRALDI is effective in people who stopped responding to or could not tolerate TNF-blocker medicines.

- **To treat moderate to severe chronic (lasting a long time) plaque psoriasis (Ps) in adults** who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).

What should I tell my doctor before taking IMRALDI?
IMRALDI may not be right for you. Before starting IMRALDI, tell your doctor about all of your health conditions, including if you:

- have an infection. See “What is the most important information I should know about IMRALDI?”
- have or have had cancer.
- have any numbness or tingling or have a disease that affects your nervous system such as multiple sclerosis or Guillain-Barré syndrome.
- have or had heart failure.
- have recently received or are scheduled to receive a vaccine. You may receive vaccines, except for live vaccines while using IMRALDI. Children should be brought up to date with all vaccines before starting IMRALDI.
- are allergic to IMRALDI or to any of its ingredients. See the end of this Medication Guide for a list of ingredients in IMRALDI.
- are pregnant or plan to become pregnant. It is not known if IMRALDI will harm your unborn baby. IMRALDI should only be used during a pregnancy if needed.
have a baby and you were using IMRALDI during your pregnancy. Tell your baby's doctor before your baby receives any vaccines.

breastfeeding or plan to breastfeed. You and your doctor should decide if you will breastfeed or use IMRALDI. You should not do both.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your doctor if you use:

- ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol) or SIMPONI® (golimumab), because you should not use IMRALDI while you are also using one of these medicines.
- RITUXAN® (rituximab), Your doctor may not want to give you IMRALDI if you have received RITUXAN® (rituximab) recently.
- IMURAN® (azathioprine) or PURINETHOL® (6-mercaptopurine, 6-MP).

Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.

How should I take IMRALDI?

- IMRALDI is given by an injection under the skin. Your doctor will tell you how often to take an injection of IMRALDI. This is based on your condition to be treated. **Do not inject IMRALDI more often than you were prescribed.**
- See the Instructions for Use inside the carton for complete instructions for the right way to prepare and inject IMRALDI.
- Make sure you have been shown how to inject IMRALDI before you do it yourself. You can call your doctor or 1-877-888-4231 if you have any questions about giving yourself an injection. Someone you know can also help you with your injection after they have been shown how to prepare and inject IMRALDI.
- **Do not** try to inject IMRALDI yourself until you have been shown the right way to give the injections. If your doctor decides that you or a caregiver may be able to give your injections of IMRALDI at home, you should receive training on the right way to prepare and inject IMRALDI.
- Do not miss any doses of IMRALDI unless your doctor says it is okay. If you forget to take IMRALDI, inject a dose as soon as you remember. Then, take your next dose at your regular scheduled time. This will put you back on schedule. In case you are not sure when to inject IMRALDI, call your doctor or pharmacist.
- If you take more IMRALDI than you were told to take, call your doctor.

What are the possible side effects of IMRALDI?

IMRALDI can cause serious side effects, including:

See “What is the most important information I should know about IMRALDI?”

- **Serious Infections.**
  - Your doctor will examine you for TB and perform a test to see if you have TB. If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with IMRALDI and during treatment with IMRALDI. Even if your TB test is negative your doctor should carefully monitor you for TB infections while you are taking IMRALDI. People who had a negative TB skin test before receiving adalimumab have developed active TB. Tell your doctor if you have any of the following symptoms while taking or after taking IMRALDI:
  - cough that does not go away
  - low grade fever
  - weight loss
  - loss of body fat and muscle (wasting)

- **Hepatitis B infection in people who carry the virus in their blood.**
  - If you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus can become
active while you use IMRALDI. Your doctor should do blood tests before you start treatment, while you are using IMRALDI, and for several months after you stop treatment with IMRALDI. Tell your doctor if you have any of the following symptoms of a possible hepatitis B infection:

- muscle aches
- feel very tired
- dark urine
- skin or eyes look yellow
- little or no appetite
- vomiting
- clay-colored bowel movements
- fever
- chills
- stomach discomfort
- skin rash
- clay-colored bowel movements

**Allergic reactions.** Allergic reactions can happen in people who use adalimumab products. Call your doctor or get medical help right away if you have any of these symptoms of a serious allergic reaction:

- hives
- trouble breathing
- swelling of your face, eyes, lips or mouth

**Nervous system problems.** Signs and symptoms of a nervous system problem include: numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness.

**Blood problems.** Your body may not make enough of the blood cells that help fight infections or help to stop bleeding. Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale.

**New heart failure or worsening of heart failure you already have.** Call your doctor right away if you get new worsening symptoms of heart failure while taking IMRALDI, including:

- shortness of breath
- sudden weight gain
- swelling of your ankles or feet

**Immune reactions including a lupus-like syndrome.** Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or a rash on your cheeks or arms that gets worse in the sun. Symptoms may improve when you stop IMRALDI.

**Liver Problems.** Liver problems can happen in people who use TNF-blocker medicines. These problems can lead to liver failure and death. Call your doctor right away if you have any of these symptoms:

- feel very tired
- poor appetite or vomiting
- skin or eyes look yellow
- pain on the right side of your stomach (abdomen)

**Psoriasis.** Some people using adalimumab products had new psoriasis or worsening of psoriasis they already had. Tell your doctor if you develop red scaly patches or raised bumps that are filled with pus. Your doctor may decide to stop your treatment with IMRALDI.

Call your doctor or get medical care right away if you develop any of the above symptoms. Your treatment with IMRALDI may be stopped. Common side effects with adalimumab products include:

- injection site reactions: redness, rash, swelling, itching, or bruising. These symptoms usually will go away within a few days. Call your doctor right away if you have pain, redness or swelling around the injection site that does not go away within a few days or gets worse.
- upper respiratory infections (including sinus infections)
- headaches
- rash
How should I store IMRALDI?

- Store IMRALDI in the refrigerator at 36°F to 46°F (2°C to 8°C). Store IMRALDI in the original carton until use to protect it from light.
- **Do not freeze IMRALDI.** Do not use IMRALDI if frozen, even if it has been thawed.
- Refrigerated IMRALDI may be used until the expiration date printed on the IMRALDI carton, dose pack, pre-filled pen. Do not use IMRALDI after the expiration date.
- If needed, for example when you are traveling, you may also store IMRALDI at room temperature up to 77°F (25°C) for up to 14 days. Store IMRALDI in the original carton until use to protect it from light.
- Throw away IMRALDI if it has been kept at room temperature and not been used within 14 days.
- Record the date you first remove IMRALDI from the refrigerator in the spaces provided on the carton and dose tray.
- Do not store IMRALDI in extreme heat or cold.
- Do not use a pre-filled pen if the liquid is cloudy, discolored, or has flakes or particles in it.
- Do not drop or crush IMRALDI.

**Keep IMRALDI, injection supplies, and all other medicines out of the reach of children.**

General information about the safe and effective use of IMRALDI

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use IMRALDI for a condition for which it was not prescribed. Do not give IMRALDI to other people, even if they have the same condition. It may harm them.

This Medication Guide summarizes the most important information about IMRALDI. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about IMRALDI that is written for health professionals. For more information go to www.XXXXXXXX.com or call Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. at 1-877-888-4231.

What are the ingredients in IMRALDI?

**Active ingredient:** adalimumab

IMRALDI Pre-filled Pen 40 mg/0.8 mL:

**Inactive ingredients:** trisodium citrate dihydrate, citric acid monohydrate, histidine, histidine monohydrochloride monohydrate, sorbitol, polysorbate 20, and Water for Injection.

Manufactured by: Samsung Bioepis Co., Ltd., 107, Cheomdan-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea

Manufactured for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ 07033 USA

US License Number 2046

This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: MM/YYYY
The following instructions are for preparing and giving a dose of IMRALDI Pre-filled Pen using a single-dose pen. Read this Instructions for Use before you start using IMRALDI Pre-filled Pen.

**Your single-dose pre-filled pen:**

There is no button on your pre-filled pen. The needle is hidden below the green base. When you push the pre-filled pen firmly onto your skin, the injection will start automatically.

**Step 1: Gather supplies**
- Place your pre-filled pen and alcohol swabs on a clean, dry surface.
- Remember to wash your hands.
- Don't remove the cap just yet.

**Step 2: Wait 15-30 minutes**
- Wait 15-30 minutes for your pre-filled pen to reach to room temperature, which helps to reduce pain during injection.
- Don't remove the cap just yet.

**Step 3: Inspect medicine & date**
- Always make sure your medicine is clear, free of particles, and hasn't expired.
• You may see an air bubble, and that's okay.
• Don't remove the cap just yet.

Step 4: Choose site & clean skin
• Choose an injection site on your body.
• Your abdomen or thighs are best.
• Wipe the injection site with an alcohol swab.
• Avoid skin that's sore, bruised, scarred, scaly or has red patches.

Step 5: Pull off the clear needle cap
• Carefully pull off the needle cap with a metal center from the pen.

Step 6: Place green base, press down, and hold
• Place the green base straight on your skin, and push the entire pre-filled pen down firmly to start the injection.
• When you push down, the injection starts.
• You may hear a 1st click.
**Step 7: Continue to hold**
- Hold the pen against your skin until the yellow indicator fills the medication window and stops moving.
- Several seconds later you may hear a 2\textsuperscript{nd} click.

**Step 8: Confirm completion & dispose pen**
- Confirm that the entire medication window is yellow.
- Discard your pre-filled pen in a sharps container.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Manufactured by: Samsung Bioepis Co., Ltd., 107, Cheomdan-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea
U.S. License No. 2046
Manufactured for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ 07033 USA
Last Revised <MM/YYYY>

**Principal Display Panel – Imraldi Pre-filled Pen Label**
NDC 71202-002-02

Imraldi
EXP:

(adalimumab-xxxx)
injection

LOT:

40 mg/0.8 mL

Single-Dose Pre-filled Pen
For Subcutaneous Use only
Rx only

Manuf by: Samsung Bioepis Co., Ltd.
Incheon, 21987 Republic of Korea
License No. 2046
Manuf for: Merck Sharp & Dohme Corp.,
a subsidiary of Merck & Co., Inc.
Principal Display Panel – Imraldi Pre-filled Pen Carton Label

NDC 71202-002-02

40 mg
MERCK
Imraldi
(adalimumab-xxxx)
Injection
40 mg/0.8 mL Pre-filled Pen
For Subcutaneous Use Only
2 single-dose pre-filled pens
Dispense the enclosed Medication Guide to each patient.

The entire carton is to be dispensed as a unit. This carton contains:
- 2 single-dose pre-filled pens
- 1 package insert
- 1 Medication Guide
- 1 Instruction for Use

There is NO BUTTON on your pen. Each pre-filled pen contains 40 mg/0.8 mL adalimumab-xxxx.

Rx only

SAMSUNG BIOEPIS
# IMRALDI

adalimumab injection, solution

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>SUBCUTANEOUS</td>
<td>NDC:71202-002</td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab (UNII: FYS6T7F842) (Adalimumab - UNII:FYS6T7F842)</td>
<td>Adalimumab</td>
<td>40 mg in 0.8 mL</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisodium Citrate Dihydrate (UNII: B22547B95K)</td>
<td></td>
</tr>
<tr>
<td>Citric acid monohydrate (UNII: 2968PHW8QP)</td>
<td></td>
</tr>
<tr>
<td>Histidine (UNII: 4QD397987E)</td>
<td></td>
</tr>
<tr>
<td>Histidine Monohydrochloride Monohydrate (UNII: X573657P6P)</td>
<td></td>
</tr>
<tr>
<td>Sorbitol (UNII: 506T60A25R)</td>
<td></td>
</tr>
<tr>
<td>Polysorbate 20 (UNII: 7T1F30V5YH)</td>
<td></td>
</tr>
</tbody>
</table>

## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:71202-002-02</td>
<td>2 in 1 CARTON</td>
<td>10/17/2018</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1 in 1 DOSE PACK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1 mL in 1 SYRINGE, GLASS; Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)</td>
<td>10/17/2018</td>
<td></td>
</tr>
</tbody>
</table>

## Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Export only</td>
<td></td>
<td>10/17/2018</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Samsung Bioepis Co., Ltd. (557822226)

**Registrant** - Samsung Bioepis Co., Ltd. (557822226)

Revised: 1/2018